News|Articles|September 2, 2026

Eyes on August 2026: MIGS momentum, myopia research, and AI's reality check

Cataract safety, Glaucoma drugs and MIGS, plus Artificial Intelligence debates and retina breakthroughs—key FDA moves and trial updates in ophthalmology.

Retina specialists weighed in on the FDA's approval of bevacizumab-vikg (Lytenava) for wet age-related macular degeneration, reacting to the arrival of a lower-cost, ophthalmic-specific bevacizumab option and discussing what it could mean for treatment paradigms and off-label compounding practices going forward.